Comparison Breakdown,Ht31 peptide is a 24-residue peptide

The ht31 peptide structure is a topic of significant interest within molecular biology and pharmacology due to its crucial role in regulating protein kinase A (PKA) activity. This peptide functions as a potent inhibitor of PKA anchoring, a process vital for the spatial and temporal control of cellular signaling pathways. Understanding the intricacies of the Ht31 peptide structure is fundamental to comprehending its mechanism of action and its potential therapeutic applications.

At its core, the Ht31 peptide is a 24-residue peptide. This specific sequence is derived from the PKA-anchoring domain of A-kinase anchoring proteins (AKAPs), such as AKAP-Lbc. The defining characteristic of Ht31 is its ability to adopt a specific secondary structure, which is paramount for its high-affinity binding to the regulatory subunit RII of PKA. This interaction effectively prevents the catalytic subunit of PKA from associating with its anchoring protein, thereby disrupting the formation of localized PKA signaling complexes.

Research has demonstrated that the Ht31 peptide can adopt an alpha-helical conformation when bound to RII. This amphipathic helical structure is critical for its function. The helical wheel analysis of Ht31 and other related peptides like AKAP79 reveals that their side chains converge into a more defined space, facilitating precise interactions with the RII subunit. This precise structural arrangement allows Ht31 to act as a competitive inhibitor, directly competing with endogenous AKAPs for binding to PKA RII subunits.

Further modifications of the Ht31 peptide have been explored to enhance its properties. For instance, st-Ht31 is a stearated form of the peptide Ht-31. This modification enhances its membrane permeability, making st-Ht31 a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. This enhanced cell-penetration allows st-Ht31 to exert its inhibitory effects within the cellular environment more effectively. Another derivative, Ht31P, is a related peptide that incorporates a proline substitution within its sequence. This modification is designed to disrupt the amphipathic helix formation and, consequently, its ability to bind RII, serving as a crucial negative control in experimental settings. Similarly, S-Ht31-P, identical to S-Ht31 except for a proline for isoleucine substitution, also demonstrates the importance of the helical structure for binding.

The structural insights into Ht31 have been elucidated through various biophysical techniques, including Nuclear Magnetic Resonance (NMR) spectroscopy. Studies examining the structures of D/D-AKAP peptide complexes, including one with Ht31(493-515), reveal that the Ht31 and AKAP79 peptides are ordered and overlay well when bound to RIIα D/D. This detailed structural information is vital for understanding the molecular basis of AKAP-PKA interactions.

The implications of the Ht31 peptide structure extend to various biological processes. By disrupting PKA anchoring, Ht31 can influence a wide range of cellular functions regulated by PKA, including inflammatory pain pathways. It has been shown that the Ht31 peptide inhibited inflammatory pain by blocking NMDA receptor-mediated nociceptive transmission in the spinal dorsal horn of mice. Furthermore, Ht31 has been observed to induce robust cholesterol/phospholipid efflux, suggesting a role in cellular lipid metabolism.

In summary, the ht31 peptide structure is characterized by its 24-residue length and its ability to form a specific secondary structure, typically an amphipathic alpha-helix. This structural feature is the basis for its potent inhibitory activity against the interaction between PKA RII subunits and AKAPs. Modified versions like st-Ht31 offer improved cell permeability, while Ht31P and S-Ht31-P serve as critical controls highlighting the importance of the helical conformation. The detailed understanding of the classical Ht31 peptide's structure and function continues to be a cornerstone for research into PKA signaling and the development of novel therapeutic strategies.